The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers
ROCKVILLE, Md. and SUZHOU, China, Oct. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major diseases, is pleased to see that the National Medical Products Administration (NMPA) of China has approved the New Drug Application (NDA)...
The China NMPA Approved CYRAMZA® (ramucirumab) for the Treatment in Patients with Hepatocellular Carcinoma
ROCKVILLE, Md. and SUZHOU, China, Oct. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major diseases, is pleased to see that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA)...
Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19
--The multiple-dose escalation Phase I clinical trial will enroll 72 healthy subjects including 60 subjects in 6 dose escalation cohorts and 12 subjects in food effect trial. The enrollment is expected to be completed in the fourth quarter of 2022 --ASC10 is an oral double prodrug. After oral administration, both ASC10 and single prodrug molnupiravir...
Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an oral small molecule GLP-1 receptor agonist for the Treatment of Obesity and Type 2 Diabetes
HANGZHOU, China and SAN FRANCISCO, Oct. 10, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today the initiation of dosing in a Phase 1 clinical trial evaluating XW014, a novel oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. XW014 is being developed for...
WuXi Biologics Co., Ltd. Removed from Unverified List
WUXI, China, Oct. 10, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics Co., Ltd. located in Wuxi city was removed from the Unverified List (UVL) by the U.S. Department of Commerce, effective October 7, 2022. In February 2022, two subsidiaries of WuXi Biologics,...
AXA BetterMe Weekend concludes on a high note
Brand Ambassador Sammi Cheng motivates the public to become a BetterMe HONG KONG, Oct. 9, 2022 /PRNewswire/ -- To mark World Mental Health Day on 10 October, AXA Hong Kong and Macau ("AXA") brought back the AXA BetterMe Weekend on 8 and 9 October 2022 at AXA x WONDERLAND @West Kowloon Cultural District, to encourage the public to take...
Mediterranean diet improves immunotherapy response rates and progression-free survival in advanced melanoma, new study presented at UEG Week suggests
VIENNA, Oct. 9, 2022 /PRNewswire/ -- Eating a Mediterranean diet, rich in fibre, mono-unsaturated fatty acids and polyphenols, has been associated with improved immunotherapy response rates and progression-free survival in advanced melanoma patients, a new study presented today at UEG Week 2022 has found. Experts anticipate that the diet will play an important role in the success of immunotherapy...
Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting
Oral presentation highlights preclinical data of ATG-031, an in-house discovered anti-CD24 monoclonal antibody Three poster presentations showcase preclinical data of ATG-101, a PD-L1/4-1BB bispecific antibody developed in-house, ATG-018, an ATR inhibitor discovered in-house, and ATG-027, a B7H3/PD-L1 bispecific antibody discovered in-house Antengene has global rights to these pipeline assets SHANGHAI and...
Everest Medicines Announces Approval of XERAVA® in Hong Kong for the Treatment of Complicated Intra-Abdominal Infections
SHANGHAI, Oct. 8, 2022 /PRNewswire/ -- Everest Medicines Limited (HKEX 1952.HK, "Everest Medicines", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asia, announced today that the Department of Health of the Hong Kong Special Administrative Region, China, has approved a New Drug Application (NDA) for...
First patient treated in Clarity’s therapeutic prostate cancer trial
Highlights Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604) investigating Targeted Copper Theranostics (TCTs) in patients with metastatic castrate-resistant prostate cancer (mCRPC) Data from the initial dosimetry phase with 64Cu SAR-bisPSMA was assessed by the Safety Review Committee which...
